NASDAQ: VAXXVaxxinity Inc Stock
$1.37-0.03 (-2.14%)
Updated Sep 29, 2023
VAXX Price
$1.37
Fair Value Price
N/A
Market Cap
$173.64M
52 Week Low
$1.24
52 Week High
$4.47
P/E
-2.36x
P/B
4.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$72.11M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.04
Operating Cash Flow
-$58M
Beta
0.95
Next Earnings
Nov 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A
VAXX Overview
Vaxxinity Incorporated develops products in the fields of neurology and coronaviruses in the U.S. Its pipeline includes UB-311, in Phase 2 clinical trials to treat Alzheimer's disease, UB-312 to treat Parkinson's disease, and UB-612, in Phase 3 clinical trials to neutralize the SARS-CoV-2 virus. The company was founded in 2014 and is headquartered in Dallas, TX.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VAXX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VAXX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VAXX is good value based on its book value relative to its share price (4.96x), compared to the US Biotechnology industry average (5.09x)
P/B vs Industry Valuation
VAXX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VAXX due diligence checks available for Premium users.
Be the first to know about important VAXX news, forecast changes, insider trades & much more!
VAXX News
Valuation
VAXX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.36x
Industry
13.67x
Market
12.37x
VAXX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.96x
Industry
5.09x
VAXX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VAXX's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.0M
Profit Margin
0%
VAXX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$71.4M
Liabilities
$36.4M
Debt to equity
1.04
VAXX's short-term assets ($59.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VAXX's short-term assets ($59.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VAXX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.2M
Investing
$26.6M
Financing
$126.0k
VAXX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VAXX vs Biotech Stocks
Vaxxinity Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.